Day One Biopharmaceuticals Inc.

DAWN | NASDAQ

Price Alert Chart Builder DCF Calculator

$21.53

$0 (0.00%)

At close: Apr 24, 2026, 9:30 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $2.22B

Enterprise Value $1.79B

Beta -1.75

Average Volume 4.42M

Shares Outstanding (Diluted) 103.38M

Shares Change YoY 10.42%

Institutional Ownership 78.74%

Exchange NASDAQ

ISIN US23954D1090

Price Performance

Price Change 1M 0.6%

Price Change 3M 74.6%

Price Change 6M 205.8%

Price Change YTD 143.3%

Price Change 1Y 178.2%

Price Change 3Y 73.6%

Price Change 5Y -9.1%

1M CAGR (ann.) 1.2%

1Y CAGR (ann.) 189.4%

5Y CAGR (ann.) N/A

All-Time CAGR -1.8%

Valuation

PE Ratio -20.70

Forward PE 42.04

PEG Ratio 0.40

Forward PEG 0.27

PS Ratio 14.06

Forward PS 7.20

PB Ratio 5.04

P/FCF Ratio -20.68

P/Adj. FCF Ratio -14.64

P/OCF Ratio -21.53

EV/Sales 11.29

EV/EBIT -16.34

EV/EBITDA -16.88

EV/FCF -16.61

Earnings Yield -4.8%

FCF Yield -4.8%

Adj. FCF Yield -6.8%

Financial Health

Net Cash $438.32M

Total Debt $2.79M

Cash & Short-Term Investments $441.11M

Total Assets $507.83M

Current Ratio 8.02

Quick Ratio 7.91

Debt / Equity Ratio 0.01

Debt / EBITDA -0.03

Debt / FCF -0.03

OCF / Debt -37.15

Interest Coverage 0.00

Altman Z-Score 18.80

Piotroski F-Score 3

Margins & Profitability

Gross Profit Margin 89.1%

Operating Profit Margin -80.8%

EBITDA Margin -66.7%

Net Profit Margin -67.8%

FCF Margin -68.0%

Adj. FCF Margin -96.1%

SBC / Revenue 28.1%

SBC Impact (per share) -41.3%

Returns

Return on Assets -21.1%

Return on Equity -23.4%

Return on Invested Capital -28.0%

Return on Capital Employed -28.6%

Return on Tangible Assets -21.9%

Historical Growth (CAGR)

Revenue CAGR 3Y 82.0%

Revenue CAGR 5Y 77.3%

Revenue CAGR 10Y N/A

EPS CAGR 3Y 41.7%

EPS CAGR 5Y 23.5%

EPS CAGR 10Y N/A

FCF CAGR 3Y 15.6%

FCF CAGR 5Y -14.1%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 12

EPS Growth Next 3Y 73.4%

Revenue Growth Next 3Y 49.9%

Earnings Date May 4, 2026

EPS Estimate (next Q) -$0.31

EPS Growth Est (next Q) -11.4%

Revenue Est (next Q) $54.34M

Revenue Growth Est (next Q) 76.7%

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $31.30

Price Target Upside 45.4%

Cash Flow

Operating Cash Flow $-103.76M

Free Cash Flow $-107.58M

Adj. Free Cash Flow $-151.97M

FCF Per Share -$1.04

OCF Per Share -$1

OCF/S Ratio -65.6%

Income Statement

Revenue $158.18M

Gross Profit $140.97M

Operating Income $-127.75M

EBITDA $-105.82M

Net Income $-107.32M

EPS (Diluted) -$1.04

Revenue / Employee $873.93K

Profit / Employee $-592.94K

Employees 181